AMP-activated protein kinase (AMPK), which was activated by an antihyperglycemic drug metformin, has been hypothesized to mediate metabolic adaptations. The purposes of the present study were 1) to confirm whether acute metformin administration induced AMPK phosphorylation, and 2) to determine whether chronic metformin treatment increased the peroxisome proliferator-activated receptor coactivator-1 (PGC-1 ) protein expression, glycolytic and oxidative enzyme activities, and cytochrome C and glucose transporter-4 (GLUT-4) protein expressions in the rat soleus and red and white gastrocnemius muscles. The single oral administration of metformin (300 mg/kg body weight) enhanced the AMPK phosphorylation at 5 and/or 6 hours after treatment. In the chronic study, rats were fed either normal chow or chow containing 1 % metformin for 14 days. Metformin treatment resulted in a mean daily metformin intake of 631 mg/kg body weight/day. Metformin increased the PGC-1 content in all three muscles. Metformin increased the hexokinase activity in the white gastrocnemius, the citrate synthase activity in all three muscles, and the -hydroxyacyl CoA dehydrogenase activity in the soleus. The cytochrome C protein content in the soleus muscle also increased. The GLUT-4 content was unchanged by metformin. These results suggest that metformin enhances the PGC-1 expression and mitochondrial biogenesis possibly at least in part via AMPK phosphorylation in the skeletal muscle. Metformin has thus been proposed to possibly ameliorate insulin resistance, at least partially, by means of such metabolic effects.
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Introduction
One of the key pathogenic features of type II diabetes is the metabolic abnormalities characteristic of insulin resistance (9) . The oxidative enzyme capacity in skeletal muscle was found to be reduced in the patients with type II diabetes (18, 22) . This metabolic characteristic is associated with an impaired insulin sensitivity (4, 22, 42) . The skeletal muscle oxidative enzyme capacity is thus a good predictor of insulin sensitivity (4) . A reduced mitochondrial oxidative enzyme activity in skeletal muscle is thus proposed to lead to the development of insulin resistance and it is also one of the potential therapeutic targets for insulin resistance.
Metformin, an insulin-sensitizing biguanide, is one of the most commonly used drugs to treat type II diabetes (23) . Metformin lowers the blood glucose level mainly via hepatic glucose output and insulin-stimulated glucose uptake in skeletal muscle and adipocytes (7, 23) . Furthermore, both experimental and epidemiological researches suggest that metformin might have additional cardiovascular protective actions beyond its antihyperglycemic properties (7, 23) . Despite more than 40 years of clinical use, their mechanisms of action still remain obscure. Recent studies have been demonstrated that the metformin activates the skeletal muscle 5'-AMP-activated protein kinase (AMPK) both in vivo (32) and in vitro (10, 56) .
AMPK is composed of the catalytic kinase subunit and regulatory subunits and (50).
The phosphorylation of threonine 172 in subunit is strongly associated with the AMPK activity (34, 43) . The AMPK is activated by energy deprivation such as a decreased intracellular ATP concentration and/or an increased AMP concentration (50) . The AMPK phosphorylation can be regulated by upstream kinases including LKB1 (40, 53) and Ca2+/calmodulin-dependent protein kinase kinases (16, 20, 52) . In skeletal muscle, AMPK is Page 3 of 37 JAP-00255-2006 .R2 4 mainly regulated by LKB1 (39) . Although the mechanism whereby metformin activates AMPK is not fully understood, effects of metformin in controlling the blood glucose level are mainly due to hepatic LKB1-AMPK pathway (41) . Metformin treatment to the patients with type II diabetes decreases ATP level in human skeletal muscle (32) . On the other hand, in vitro treatment of metfomin increases AMPK activity without any changes of AMP:ATP ratio in skeletal muscle cells (10) . Therefore, metformin would activate skeletal muscle AMPK through both AMP:ATP level-dependent and -independent mechanisms. Skeletal muscle AMPK is activated by exercise (6, 11) , leptin (30) , and adiponectin (55) as well as metformin (10, 32, 56) . The activation of AMPK by its specific activator 5-aminoimidazole-4-carboxamide-1--D-ribofranoside (AICAR) stimulates the glucose uptake and fatty acid oxidation in skeletal muscle cells (17, 29) . In addition, chronic AICAR-treatment increases insulin-stimulated glucose uptake, insulin signaling such as phosphatidylinositol 3-kinase and protein kinase B activities, glucose transporter 4 (GLUT-4) protein expression, hexokinase (HK) activity, and mitochondrial oxidative enzyme activities in skeletal muscle (5, 19, 21, 33, 38, 44, 51) .
The activation of AMPK by AICAR also increases the peroxisome proliferator-activated receptor coactivator-1 (PGC-1 ) expression in skeletal muscle (24, 44, 45) . PGC-1 is a nuclear-encoded transcriptional coactivator and it plays an important role in mitochondrial biogenesis, glucose metabolism, muscle fiber pattern, and adaptive thermogenesis (25, 26, 37, 54) . PGC-1 is associated with insulin sensitivity and type II diabetes (8, 15, 27, 31, 35) . The inhibition of PGC-1 by small interfering RNA prevents AICAR-induced fatty acid oxidation in C 2 C 12 muscle cells (24) . It is therefore plausible that the increased skeletal muscle mitochondrial oxidative enzyme activity by activation of AMPK (38, 44, 51) is at least Metformin treatment has been hypothesized to increase PGC-1 protein expression and oxidative enzyme activities as well as HK activity and GLUT-4 expression via AMPK phosphorylation in skeletal muscle. The current study was conducted 1) to confirm whether oral metformin treatment in rats induced AMPK phosphorylation in skeletal muscle and 2) to determine whether chronic metformin treatment increased the PGC-1 protein expression and metabolic components including the activity of glycolytic and oxidative enzymes and GLUT-4 protein expression in rat skeletal muscle.
Materials and Methods
Animals
Eight-week-old male Wistar rats with a body weight of 250-280 g (Kyudo, Tosu, Saga, Japan) were used for the current study. All rats were handled daily for at least 5 days before beginning their treatment regimen. All rats were housed in a temperature-(22 ± 2°C) and humidity-controlled (60 ± 5%) room with a 12-hour light (7:00 to 19:00) and 12-hour dark (19:00 to 7:00) cycle. All experimental procedures were strictly conducted in accordance with the Nakamura Gakuen University guidelines for the Care and Use of Laboratory Animals and were approved by the University Animal Experiment Committee.
Protocol for acute treatment study
To determine both the AMPK and acetyl CoA carboxylase (ACC) phosphorylation with acute metformin treatment, metformin hydrochloride (Dainippon Sumitomopharma, Osaka, Japan) (300 mg/kg body weight) in saline was orally administered in the metformin-treated group (n = 24). This dose of metformin was sufficient to decrease blood glucose level and 
Protocol for chronic treatment study
The rats were divided into a control group (n = 8) or a metformin-treated group (n = 8).
The rats of the metformin-treated group were fed powdered regular rat chaw (Oriental Yeast, Tokyo Japan), containing 1% metformin by weight and water ad libitum for 14 days. The control group was pair-fed with regular rat chaw. On the day of sampling, the chaw was sodium dodecylsulfate, 10% glycerol, 5% ß-mercaptoethanol, and 0.005% bromophenol blue).
For PGC-1 protein determination, the samples were boiled for 5 min to avoid either a high background or non-specific bands. For cytochrome C and GLUT-4 protein determinations, To determine the phospho-and total AMPK and ACC protein levels, remaining soleus and white gastrocnemius muscle samples were homogenized as described in the Protocol for acute treatment study.
Gel electrophoresis and Western blotting
The proteins (20 µg) of these homogenates were separated by sodium-dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 5.5%
(phospho-and total ACC), 7.5% (PGC-1 ), 10% (phospho-and total AMPK and GLUT-4), 
Enzyme assay
The enzyme activities were measured spectrophotometrically. All enzymatic assays were carried out at 30°C using saturating concentrations of substrates and cofactors as determined in preliminary analyses. Citrate synthase (CS; tricarboxylic acid cycle) activities were measured at 412 nm to detect the transfer of sulfhydryl groups to 5,5'-dithiobis(2-nitrobenzonic acid) (DTNB). HK (mobilization of blood glucose), pyruvate kinase (PK; glycolysis), lactate dehydrogenase (LDH; anaerobic glycolysis), and -hydroxyacyl CoA dehydrogenase ( HAD; oxidation) activities were measured at 340 nm by following the production or disappearance of NADH or NADPH.
For the HK (EC 2.7.1.1) assay, 100 mM Tris-HCl, 0.4 mM NADP, 5 mM MgCl 2 , 700 U/ml glucose-6-phosphate dehydrogenase, 1 mM glucose, and 5 mM ATP, pH 7.0, were used.
For the PK (EC 2.7.1.40) assay, 50 mM Tris-HCl, 0.1 mM KCl, 10 mM MgCl 2 , 0.28 mM NADH, 1.5 mM ADP, 6 U/ml LDH, and 5 mM phosphoenolpyruvate, pH 7.6, were used.
For the LDH (EC 1.1.1.27) assay, 50 mM Tris-HCl, 0.28 mM NADH, and 2.4 mM pyruvic acid, pH 7.6, were used.
For the CS (EC 4.1.3.7) assay, 100 mM Tris-HCl, 0.1 mM DTNB, 0.3 mM acetyl-CoA, 3.33 mM K 2 HPO 4 , and 0.5 mM oxalacetate, pH 8.0, were used.
For the HAD (EC 1.1.1.35) assay, 100 mM Tris-HCl, 0.28 mM NADH, 5 mM EDTA, and 0.1 mM acetoacetyl-CoA, pH 6.9, were used. 
Statistical analysis
All data are expressed as the means ± SE. The unpaired t-test was used to compare between the control and metformin-treated groups. A value of P < 0.05 was considered to be significant.
Results
Western blotting for AMPK and ACC in the acute study Figure 1 shows the Western blot detections of phospho-AMPK protein in the muscles. The denstitometric data indicated that the AMPK phosphorylation levels of the metformin-treated group 5 hours after administration of metformin in the white gastrocnemius muscle was significantly higher than that of the saline-treated control group (+18%, P = 0.046). In addition, 6 hours after metformin administration, the AMPK phosphorylation levels were significantly higher than those of the control group in the soleus (+35%, P = 0.030) and red (+54%, P = 0.005) and white (+46%, P = 0.017) gastrocnemius muscles. On the other hand, at 1 or 4 hours after metformin-administration in any muscles or at 5 hours after the injection in the soleus or red gastrocnemius muscle, the AMPK phosphorylation levels were not altered.
Total AMPK, phospho-ACC, and total ACC protein expression 6h after a single administration of mertformin were also determined ( Table 1 ). The ACC phosphorylation levels were significantly increased in all three muscles investigated. On the other hand, the total AMPK and ACC protein levels were not altered by metformin administration.
Animal characteristics in the chronic study
Body, muscle, and epididymal fat tissue weights in metformin-treated group were (Table 2) . The blood glucose and lactate levels in metformin-treated group were not different from those in control group (Table 2) . On the other hand, serum insulin level in metformin-treated group was significantly lower than that in the control group (P = 0.006, respectively). 
AMPK and ACC protein expressions in the chronic study
Phospho-and total AMPK and ACC protein expressions in the soleus and white gastrocnemius muscles with chronic metformin treatment were determined. The phospho-or total AMPK protein levels were not altered by metformin treatment (data not shown). The phospho-ACC protein levels in the metformin-treated group were significantly higher in the soleus (+55%, P = 0.021) and white gastrocnemius muscles (+32%, P = 0.015). The total ACC protein levels were not altered by metformin treatment (data not shown). Because ACC is a downstream target of AMPK, it was speculated that AMPK activity was in fact elevated by metformin in vivo. Figure 3A shows representative Western blot detections of PGC-1 protein in the muscles.
PGC-1 protein expression
An immunoreactive band of ~120 kDa was detected on Western blotting. This molecular weight of the PGC-1 protein seems to be identical with the previous studies (47) . Other studies demonstrated that the molecular weight of PGC-1 protein was ~ 90kDa (49) . The reason about this difference is unknown at present. Figure 3B shows the mean values of PGC-1 protein content in the muscles. The denstitometric data indicated that the PGC-1 protein levels of the metformin-treated group were significantly higher than those of the control group in the soleus (+49%, P = 0.003) and red (+35%, P = 0.006) and white (+79%, P = 0.011) gastrocnemius muscles. Figure 4 indicates the muscle enzyme activities. The HK activity of the metformin treated group in the white gastrocnemius muscle was significantly higher than that of control group (+24%, P = 0.021) while such differences were not observed in the soleus or red gastrocnemius muscles ( Figure 4A ). The PK activity of the metformin treated group in the white gastrocnemius muscle was significantly higher than that of the control group (+11%, P = 0.019) while such differences were not observed in the soleus or red gastrocnemius muscles ( Figure 4B ). The LDH activities in any muscles were not altered by the metformin treatment ( Figure 4C ). The CS activities of metformin treatment group were significantly higher than in the control group in the soleus (+17%, P = 0.012) and red (+19%, P = 0.006) and white (+41%, P = 0.016) gastrocnemius muscles ( Figure 4D ). The HAD activity of metformin treated group in the soleus muscle was significantly higher than that of the control group (+20%, P = 0.013) while no differences were observed in the red or white gastrocnemius muscles ( Figure 4E ). Figure 5A shows the Western blot detections of the cytochrome C protein in the muscles.
Enzyme activities
Cytochrome C and GLUT-4 protein expressions
The cytochrome C protein content of the metformin treated group in the soleus muscle was significantly higher than that of control group (+35%, P = 0.046). In the white gastrocnemius muscle, cytochrome C protein content was tended to be high (+18%, P = 0.078). No significant difference was observed in the red gastrocnemius muscle. Figure 5B shows the Western blot detections of the GLUT-4 protein in the muscles. No significant differences were observed in any muscles between the groups.
Discussion
The present study is the first to demonstrate that 5 to 6 hours are required for AMPK phosphorylation to be enhanced in skeletal muscle after the acute oral administration of metformin. In addition, chronic metformin treatment increases the skeletal muscle PGC-1 protein expression, HK activity, mitochondrial oxidative enzyme activities, and cytochrome C protein expression in vivo. Although we did not indicate any direct evidence, it
is possible that such increments may at least partially be attributed to AMPK phosphorylation. There are many observations that PGC-1 is associated with type II diabetes and insulin sensitivity. The genetic polymorphism of the PGC-1 gene (Gly482Ser) has been shown to be linked to type II diabetes (8, 15) . The PGC-1 expression in skeletal muscle is significantly lower in the patients with type II diabetes and in family history-positive nondiabetic subjects (first-degree relative) than in family history-negative nondiabetic patients (35) . The genes involved in oxidative phosphorylation, whose expression is regulated by PGC-1 have been
shown to be downregulated in skeletal muscle of type II diabetic patients (31) . Skeletal muscle PGC-1 expression after a hyperinsulinemic clamp is related to the insulin sensitivity (27) . Collectively these observations strongly suggest that the skeletal muscle PGC-1 plays an important role in insulin sensitivity and development of type II diabetes. It is well known that the metformin improves insulin sensitivity in the patients with type II diabetes (23) . It is likely that such a benefit of metformin, at least in part, results from an improvement of skeletal muscle PGC-1 expression.
The current study demonstrated that the metformin treatment increased the skeletal muscle mitochondrial CS activity in the soleus and red and white gastrocnemius muscles. In addition, the HAD activity also significantly increased in the soleus muscle with metformin treatment. This increment of mitochondrial oxidative enzyme activities with metformin would at least partially be expected to be due to the increased PGC-1 protein expression. A previous study demonstrated the forced expression of PGC-1 to stimulate mitochondrial proliferation, while increasing the mtDNA copy number, and upregulating the transcriptional factors involving mitochondrial biogenesis such as nuclear respiratory factor 1 (NRF-1) and 2
(NRF-2) and mitochondrial transcription factor A (mtTFA) in C 2 C 12 skeletal muscle cells (54) . It has been postulated that an impaired mitochondrial oxidative capacity could be a direct cause of insulin resistance (12) . The offspring of type II diabetic parents, considered to possess the highest risk for developing type II diabetes (48), show reduced mitochondrial activity in skeletal muscle as well as insulin resistance (36) . Furthermore, a decreased skeletal muscle mitochondrial size or oxidative enzyme activity is related to insulin resistance and type II diabetes (4, 18, 22, 42) . Taken together, a decreased mitochondrial oxidative enzyme activity in skeletal muscle can be one of the primary candidates for developing type II diabetes. Therefore, the enhancement of the mitochondrial capacity is potentially effective for ameliorating or preventing the insulin resistance or type II diabetes. It is speculated that the effectiveness of metformin for improving insulin sensitivity by the insulin-stimulated glucose uptake in skeletal muscle, as described elsewhere (23), may therefore be at least in part due to the enhanced skeletal muscle mitochondrial capacity.
In this study we demonstrated that the metformin treatment to normal rats for 14 days increased the HK activity of white gastrocnemius muscle. A previous study also demonstrated that the skeletal muscle HK activity increased by metformin treatment (250 mg/kg/day for 3 weeks) in the streptozotocin-induced diabetic mice (3). Because activation of AMPK by AICAR treatment increased HK activity of skeletal muscle (19, 33, 44, 51) , it is suggested that metformin enhances the HK activity via AMPK activation in skeletal muscle. Previous studies demonstrated the HK activity to be strongly associated with insulin sensitivity and insulin-stimulated skeletal muscle glucose uptake (13) , suggesting that an increased HK activity as well as mitochondrial oxidative enzymes in skeletal muscle may also contribute to the blood glucose-lowering effect of metformin in the patients with insulin-resistant type II diabetes.
It is important to note that 5 to 6 hours are required to phosphorylate AMPK with an oral single injection of metformin to rats in the current study. In contrast, intraperitoneal injection of AICAR to rats increased AMPK phosphorylation at 30 minutes after injection (2) .
Collectively these data imply that the action of metformin regarding AMPK phosphorylation is much milder than that of AICAR. The blood metformin concentration is expected to reach highest ~3 hours after the oral metformin treatment (7). In addition, 3 hours of incubation are needed to enhance the AMPK activity of skeletal muscle when the isolated rat epitrochlearis muscle is incubated with metformin (56). Therefore, it seems to be reasonable that the AMPK phosphorylation in skeletal muscle occurs at 5 and/or 6 hours after oral metformin injection.
Furthermore, the AMPK phosphorylation was not increased whereas ACC phosphorylation was increased after 2 weeks of chronic metformin treatment by containing metformin in powder chow in the present study. This strategy of metformin treatment may therefore be another cause for the milder effect of metformin. In line with such a milder effect, the level of increased PGC-1 protein expression by 14-day treatment of metformin in this experiment (35 to 79% of control) seems to be lower than that of AICAR (87 to 114% of control) (44) .
Although the reason why metformin does not increase the HAD activity or cytochrome C protein expression in red or white gastrocnemius muscles or the HK activity in the soleus or red gastrocnemius muscles is unknown at present, it is possible that such a mild effect of While the reason why metformin does not increase the GLUT-4 in vivo is unclear at present, it is possible that some unknown mechanisms that inhibit the GLUT-4 expression or promote degradation might exist. Such mechanisms might prevent the enhancement of GLUT-4 expression via the AMPK signaling in normal Wistar rats of this study or overcome the AMPK signaling in Fa/-rats of the previous study (14) . Further studies are called for to clarify the difference between the action of metformin and AICAR for skeletal muscle GLUT-4 expression in vivo.
In conclusion, single oral metformin administration to rats increases the AMPK phosphorylation in skeletal muscle 5 to 6 hours after administration. In addition, chronic Control Metformin n = 6 n = 6 n = 6 n = 6 n = 6 n = 6
Total AMPK 100 ± 9 101 ± 4 100 ± 4 100 ± 3 100 ± 8 92 ± 6
Phospho-ACC 100 ± 9 141 ± 10* 100 ± 13 152 ± 9* 100 ± 12 190 ± 17* Total ACC 100 ± 8 100 ± 10 100 ± 5 98 ± 4 100 ± 17 102 ± 8 Soleus Red Gastroc. White Gastroc. Data are expressed as the mean ± SE; n = 6 muscles per group. *P < 0.05 vs. saline-treated control group at the same point of time. 
